{"title":"替西肽:治疗“糖尿病”的革命性药物","authors":"Vansh Chouhan, Simran Spal, Rakesh Kumar","doi":"10.18311/ijmds/2022/636","DOIUrl":null,"url":null,"abstract":"Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.","PeriodicalId":14010,"journal":{"name":"International Journal of Medical and Dental Sciences","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tirzepatide: Revolutionary Drug in Management of “Diabesity”\",\"authors\":\"Vansh Chouhan, Simran Spal, Rakesh Kumar\",\"doi\":\"10.18311/ijmds/2022/636\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.\",\"PeriodicalId\":14010,\"journal\":{\"name\":\"International Journal of Medical and Dental Sciences\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Medical and Dental Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18311/ijmds/2022/636\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical and Dental Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18311/ijmds/2022/636","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tirzepatide: Revolutionary Drug in Management of “Diabesity”
Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
